Lead Programs
| Programs | Potential Indication(s) | Discovery | Lead Optimization | IND-Enabling | Phase 1 | Partner |
|---|---|---|---|---|---|---|
| STAT6 Oral small molecule | Atopic dermatitis, COPD, asthma, others |  Option for 50% U.S. P&L Share | ||||
| STAT3 Oral small molecule | Psoriasis, rheumatoid arthritis, ulcerative colitis, Crohn's disease, others | Wholly-owned | ||||
| BTK Oral, SH2 domain | Chronic urticaria, rheumatoid arthritis, multiple sclerosis, others | Wholly-owned | ||||
| Pipeline Programs | Multiple inflammatory diseases | Wholly-owned | ||||
| Program | Indication | Stage | Partner | STAT6 Oral small molecule | Atopic dermatitis, COPD, asthma, others | IND-Enabling | Option for 50% U.S. P&L Share |
STAT3 Oral small molecule | Psoriasis, rheumatoid arthritis, ulcerative colitis, Crohn's disease, others | Lead Optimization | Wholly-owned | BTK Oral, SH2 domain | Chronic urticaria, rheumatoid arthritis, multiple sclerosis, others | Lead Optimization | Wholly-owned | Pipeline Programs | Multiple inflammatory diseases | Discovery | Wholly-owned |
|---|
1Recludix has the option to participate in an equal profit-sharing arrangement in the US, which includes certain co-promotion activities
STAT Inhibitors
Recludix is pursuing a novel approach to modulate the activity of the JAK/STAT family of pathways by targeting the downstream STAT proteins through inhibition of their SH2 domains. Targeting individual STAT proteins with highly selective inhibitors is expected to provide a more focused biological response than is observed with many JAK family kinase inhibitors. This may result in fewer side effects and the ability to more profoundly inhibit a specific pathway at well-tolerated doses.
Learn More
BTK Inhibitor
Recludix has a program underway to develop a next-generation BTK inhibitor by targeting the SH2 domain instead of the kinase domain, which is the target of other BTK inhibitors. Inhibiting the protein at the SH2 domain is expected to disrupt both access to downstream targets of the kinase and other pro-inflammatory scaffolding functions, which may result in enhanced efficacy and a wider therapeutic window than other BTK inhibitor approaches. Additionally, highly differentiated chemical matter has demonstrated best-in-class in vitro selectivity, conferring potential safety and efficacy advantages.
New Target Opportunities Identified with Platform
The opportunity to identify inhibitors of new targets with Recludix’s platform is vast. There are 120 SH2 domains identified in humans, and many targets that are known to play a role in disease pathology have SH2 domains. Additionally, the distinct features of Recludix’s integrated technology platform can be used to drug non-SH2 domain targets.